

Patent

Attorney Docket No. 2664/58004

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			
SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		Docket Number: 2664/58004	
Application Number 10/815,339	Filing Date March 31, 2004	Examiner Unassigned	Art Unit 1614
Invention Title CRYSTALLIZATION AND PURIFICATION OF MACROLIDES		Inventors Vilmos KERI et al.	

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited
with the United States Postal Service with sufficient
postage as first class mail in an envelope addressed to:
Mail Stop: Amendment

Commissioner for Patents, P.O. Box 1450, Alexandria, VA
22313-1450 on

Date: March 16, 2005

Signature: [Signature]
S. Ginsdin

Sir:


1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.E.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the following references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
2. Copies of patents, publications or other information listed on the modified PTO Form 1449 are enclosed, unless indicated otherwise.
3. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due the Commissioner is authorized to charge deposit account number 11-0600 for such fees.

Respectfully submitted,

Date: 3/16/05

[Signature]
John B. Starr, Jr.
Reg. No. 44,474

KENYON & KENYON
One Broadway
New York, New York 10004
(212) 425-7200 (telephone)
(212) 425-5288 (facsimile)
CUSTOMER NUMBER 26646



Substitute for Form 1449A/PTO

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/815,339
Filing Date	March 31, 2004
First Named Inventor	Vilmos KERI et al.
Art Unit	1614
Examiner Name	To be assigned
Attorney Docket Number	2664/58004

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US- 6,387,258 B1	May 14, 2002	Keri et al.	
		US- 5,200,505	April 06, 1993	Takesako et al.	
		US- 4,160,861	July 10, 1979	Cole et al.	
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Surjit S. Sengha, Fermentation, in Kirk Othmer Encyclopedia of Chemical Technology, Vol. 10, p. 361-381 (Jacquiline I. Kroschwitz, editor. 4th ed. 1993)	
		The Merck Index, Maryadele J. O'Neil et al. eds., "Pimecrolimus", page 1331, 13th ed. 2001.	
		Martindale: The complete drug reference, Sean C. Sweetman ed., "Sirolimus", page 568, Pharmaceutical Press 33rd ed. 2002	
		C.E.M. Griffiths "Ascomycin: An Advance in the Management of Atopic Dermatitis" British J. of Dermatology, V. 144, p. 679-681, (2001)	
		Martindale: The complete drug reference, Sean C. Sweetman ed., "Everolimus", page 539, Pharmaceutical Press 33rd ed. 2002	
		Zhiguo Song et al. "Highly Chemoselective Trichloracetimidate-Mediated Alkylation of Ascomycin: A Convergent, Practical Synthesis of the Immunosuppressant L-733,725" J. Org. Chem. 1999, v. 64, p. 1859- 1867	
		Jun'ichi Kobayashi et al. "Amphidinolides T2, T3, and T4, New 19-Membered Macrolides from the Dinoflagellate Amphidinium sp. and the Biosynthesis of Amphidinolide T1" J. Org. Chem. 2001, v. 66, p. 134-142	
		K. Yoshii et al. "Liquid Chromatographic Determination of Emamectin, Milbemectin, Ivermectin and Abamectin in Crops and Confirmation by Liquid Chromatography - Mass Spectrometry" Journal of Chromatography A, v. 896, 2000, p.75-85	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.